Nevirapină Accord (Nevirapine)

• Nevirapină Accord is a non‑nucleoside reverse transcriptase inhibitor indicated for HIV‑1 infection as part of combination antiretroviral therapy.
• HIV‑1 infection (treatment‑naïve adults): reduces viral load and improves immune function when combined with other antiretrovirals.
• HIV‑1 infection (treatment‑experienced adults): provides an alternative regimen after failure of other NNRTIs.
• Pediatric HIV‑1 infection (≥2 years of age): used under specialist supervision as part of a pediatric ART regimen.

• Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, inducing a conformational change that blocks the enzyme’s RNA‑ and DNA‑dependent DNA polymerase activity. This inhibition prevents the synthesis of viral DNA from the RNA template, thereby halting viral replication and reducing plasma HIV levels.

Nevirapină Accord may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are recommended.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Nausea: occasional gastrointestinal upset.
• Fatigue: feeling of tiredness or weakness.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate discontinuation.
• Hepatic failure: signs of liver injury such as jaundice or elevated enzymes.
• Severe hypersensitivity: fever, eosinophilia, or organ involvement.
• Neutropenia: low white‑blood‑cell count increasing infection risk.
• Lactic acidosis: rare metabolic disturbance with rapid breathing and abdominal pain.

Before initiating therapy with Nevirapină Accord, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline enzymes and repeat periodically.
• Skin reactions: discontinue immediately if a severe rash or mucosal involvement appears.
• Pregnancy risk assessment: evaluate benefits versus potential fetal risks.
• Drug interaction review: check all concomitant medications for hepatic enzyme effects.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nevirapină Accord can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Ritonavir‑boosted protease inhibitors: may increase nevirapine plasma concentrations.
• St. John's wort: can markedly reduce nevirapine exposure.
• Efavirenz: additive hepatotoxic potential when combined.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower nevirapine levels.
• Antacids containing aluminum or magnesium: could affect absorption if taken simultaneously.
• Methadone: may require dose adjustment due to altered metabolism.